Antiangiogenesis: A possible treatment option for prostate cancer?

Clinical Genitourinary Cancer

Volumn 4, Issue 3, 2005, Pages 197-202

  Longoria, Ritchie L ^a   Cox, Michael C ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bevacizumab; Cetuximab; Marimastat; Matrix metalloproteinase; Thalidomide; Vascular endothelial growth factor

Indexed keywords

2 METHOXYESTRADIOL; ALENDRONIC ACID; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; BATIMASTAT; BEVACIZUMAB; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; FUMAGILLOL CHLOROACETYLCARBAMATE; KETOCONAZOLE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MITOXANTRONE; PACLITAXEL; PREDNISONE; PRINOMASTAT; PROSTATE SPECIFIC ANTIGEN; SEMAXANIB; THALIDOMIDE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ASPERGILLUS FUMIGATUS; ATAXIA; BONE MARROW SUPPRESSION; CANCER GROWTH; CELL STRAIN LNCAP; CONSTIPATION; DEPRESSION; DIPLOPIA; DIZZINESS; DRUG APPROVAL; EDEMA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HEADACHE; HELA CELL; HUMAN; KAPOSI SARCOMA; KIDNEY DYSFUNCTION; LEUKEMIA CELL LINE; LIVER DYSFUNCTION; METASTASIS; MULTIPLE MYELOMA; MYALGIA; NEUROBLASTOMA CELL; NEUROTOXICITY; PROSTATE CANCER; REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW; TERATOGENICITY; THROMBOSIS PREVENTION; TINNITUS; MALE; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PROSTATE; PROSTATE TUMOR; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATIC NEOPLASMS;

EID: 33644948640     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2005.n.033     Document Type: Article

References (86)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Rini BI, Small EJ. An update on prostate cancer. Curr Opin Oncol 2001; 13:204-211.
3. Figg WD, Feuer J, Bauer KS. Management of hormone-sensitive metastatic prostate cancer. Cancer Pract 1997; 5:258-263.
4. Crawford ED, Eisenberger MA, McCleod DG, et al. A controlled trial of leuprolide with and without flutamide in prostate carcinoma. N Engl J Med 1989; 321:419-424.
5. Goktas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999; 26:162-173.
6. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000; 88:3009-3014.
7. Beedassy A, Cardi G. Chemotherapy in advanced prostate cancer. Semin Oncol 1999; 26:428-438.
8. Oh WK. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 2000; 88:3015-3021.
9. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001; 28:36-42.
10. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61:253-270.
11. Wojtowicz-Praga S, Low J, Marshall J, et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimistat (BB-94) in patients with advanced cancer. Invest New Drug 1996; 14:193-202.
12. Brown PD. Matrix metalloproteinase inhibitors in the treatment of cancer. Med Oncol 1997; 14:1-10.
13. Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2001; 94:17-25.
14. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189:300-308.
15. Parsons SL, Watson SA, Brown PD, et al. Matrix metalloproteinases. Br J Surg 1997; 84:160-166.
16. Aalkinkeel R, Nair MPN, Sufrin G et al. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 2004; 64:5311-5321.
17. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
18. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
19. Brem SS, Jensen HM, Gullino PM. Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 1978; 41:239-244.
20. Jones A, Fujiyama C. Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. BJU Int 1999; 83:535-555.
21. Bostwick DG, Iczkowski KA. Microvessel assay in prostate cancer: prognostic and therapeutic utility. Semin Urol Oncol 1998; 16:118-123.
22. Lissbrant IF, Lissbrant E, Damber J, et al. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scan 2001; 35:437-452.
23. Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995; 75:2545-2551.
24. Lissbrant IF, Stattin P, Damber J-E, et al. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. The Prostate 1997; 33:38-45.
25. Wakui S, Furusato M, Itoh T, et al. Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol 1992; 168:257-262.
26. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143:401-409.
27. Ellis LM, Liu W, Fan F, et al. Synopsis of angiogenesis inhibitors in oncology. Oncology 2002; 16 (5 suppl 4):14-22.
28. Giles FJ. The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology 2002; 16:22-29.
29. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001; 7:1888-1893.
30. Stirling D. Thalidomide: a novel template for anticancer drugs. Semin Oncol 2001; 28:602-606.
31. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:4082-4085.
32. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998; 55:1827-1834.
33. Dixon SC, Kruger KA, Bauer KS, et al. Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. Cancer Chemother Pharmacol 1999; 43:S78-S84.
34. Figg WD, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel (Taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001; 28:62-66.
35. Dahut WL, Gulley JL, Arlen PM, Liu Y, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2532-2539.
36. Horne ME 3rd, Figg WD, Arlen P, et al. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy 2003; 23:315-318.
37. Figg WD, Kruger EA, Price DK, et al. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs 2002; 20:183-194.
38. Heath EI, O'Reilly S, Humphrey R, et al. Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2001; 48:269-274.
39. Macaulay VM, O'Byrne KJ, Saunders MP, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999; 5:513-520.
40. Rudek MA, Figg WD, Dyer V, et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001; 19:584-592.
41. Nemunaitis J, Poole C, Primrose J, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998; 4:1101-1109.
42. Ahmann, FR, Saad F, Mercier R, et al. Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2002; 20:174a (Abstract #692).
43. Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999; 878:236-270.
44. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-363.
45. Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998; 90:704-708.
46. Liu Y, Figg WD, Arlen P, et al. A randomized phase II trial of ketoconazole (KT) and alendronate (AL) versus ketoconazole in androgen independent prostate cancer (AIPC). Presented at: Third North American Symposium on Skeletal Complications of Malignancy; April 25-27, 2002; Bethesda, MD. Abstract D4.
47. Kruger EA, Figg WD. TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin Invest Drugs 2000; 9:1383-1396.
48. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348:555-557.
49. Kusaka M, Sudo K, Fujita T, et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 1991; 174:1070-1076.
50. Kusaka M, Sudo K, Matsutani E, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994; 69:212-216.
51. O'Reilly MS, Brem H, Folkman J. Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J Pediatr Surg 1995; 30:325-329.
52. Koyama H, Nishizawa Y, Hosoi M, et al. The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I. Possible involvement of cyclin-dependent kinase 2. Circ Res 1996; 79:757-764.
53. Kato T, Sato K, Kakinuma H, et al. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994; 54:5143-5147.
54. Figg WD, Pluda JM, Lush RM, et al. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 1997; 17:91-97.
55. Bhargava P, Marshall JL, Rizvi N, et al. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999; 5:1989-1995.
56. Logothetis CJ, Wu KK, Finn LD, et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 2001; 7:1198-1203.
57. Stadler WM, Kuzel T, Shapiro C, et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999; 17:2541-2545.
58. Horti J, Dixon SC, Logothetis CJ, et al. Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. Br J Cancer 1999; 79:1588-1593.
59. Seegers JC, Aveling LM, Van Aswegen CH, et al. The cytotoxic effects of estradiol-17 beta, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. J Steroid Biochem 1989; 32:797-809.
60. Cushman M, He HM, Katzenellenbogen JA, et al. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 1995; 38:2041-2049.
61. Nakagawa-Yagi Y, Ogane N, Inoki Y, et al. The endogenous estrogen metabolite 2-methoxyestradiol induces apoptotic neuronal cell death in vitro. Life Sci 1996; 58:1461-1467.
62. Arbiser JL, Panigrathy D, Klauber N, et al. The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. J Am Acad Dermatol 1999; 40:925-929.
63. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368:237-239.
64. Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57:81-86.
65. Schumacher G, Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol 2001; 127:405-410.
66. Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998; 58:2269-2277.
67. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-844.
68. Mordenti J, Thomsen K, Licko V, et al. Efficacy and concentration- response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 1997; 27:14-21.
69. Warren RS, Yuan H, Matli MR, et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95:1789-1797.
70. Reese D, Frohlich M, Bok R, et al. A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhuMAb VEGF) in hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1999; 18:351a (Abstract #1355).
71. Picus J. Docetaxel/bevacizumab (Avastin) in prostate cancer. Chemotherapy Foundation Symposium XXI, 2004, New York City. Cancer Invest 2004; 22 [In press]. Available at www.mssm.edu/ctf. Accessed April 2, 2004.
72. Karashima T, Sweeney P, Slaton, JW et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002; 8:1253-1264.
73. Dang CT, Shapiro CL, Hudis CA. Potential role of selective COX-2 inhibitors in cancer management. Oncology 2002; 16:30-36.
74. Kosaka T, Miyata A, Ihara H, et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem 1994; 221:889-897.
75. Vadlamudi R, Mandal M, Adam L, et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999; 18:305-314.
76. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-1188.
77. Hwang D, Scollard D, Byrne J, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90:455-60.
78. Ristimaki A, Honkanen N, Jankala H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57:1276-1280.
79. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58:3761-3764.
80. Gupta S, Srivastava M, Ahmad N, et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42:73-78.
81. Liu XH, Yao S, Kirschenbaum A, et al. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58:4245-4249.
82. Alshafie GA, Abou-Issa HM, Seibert K, et al. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000; 7:1377-1381.
83. Liu XH, Kirschenbaum A, Yao S, et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000; 164:820-825.
84. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24:83-87.
85. Hawk E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 1999; 86:2551-2563.
86. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-1952.